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Abstract
Mutations in genes encoding nuclear enve-
lope proteins, particularly LMNA encoding the
A-type lamins, cause a broad range of diverse
diseases, referred to as laminopathies. The
astonishing variety of diseased phenotypes
suggests that different mechanisms could be
involved in the pathogenesis of laminopathies.
In this review we will focus mainly on two of
these pathogenic mechanisms: the nuclear
damages affecting the chromatin organization,
and the oxidative stress causing un-repairable
DNA damages. Alteration in the nuclear profile
and in chromatin organization, which are par-
ticularly impressive in systemic laminopathies
whose cells undergo premature senescence,
are mainly due to accumulation of
unprocessed prelamin A. The toxic effect of
these molecular species, which interfere with
chromatin-associated proteins, transcription
factors, and signaling pathways, could be
reduced by drugs which reduce their farnesyla-
tion and/or stability. In particular, inhibitors of
farnesyl transferase (FTIs), have been proved
to be active in rescuing the altered cellular
phenotype, and statins, also in association
with other drugs, have been included into pilot
clinical trials. The identification of a mecha-
nism that accounts for accumulation of un-
repairable DNA damage due to reactive oxygen
species (ROS) generation in laminopathic
cells, similar to that found in other muscular
dystrophies (MDs) caused by altered expres-
sion of extracellular matrix (ECM) compo-
nents, suggests that anti-oxidant therapeutic
strategies  might prove beneficial to lamino-
pathic patients.
Laminopathies present a widerange of diseased phenotypes
Mutations affecting the EMD gene that
encodes the inner nuclear membrane-associ-
ated protein emerin cause the X-linked form of
Emery-Dreifuss muscular dystrophy
(EDMD1).1 An indistinguishable disease phe-
notype (EDMD2) is caused  by mutations in
the LMNA gene encoding lamin A/C.2 The find-
ing that the altered expression of two different
proteins located at the nuclear envelope caus-
es a similar diseased phenotype affecting the
contractile tissues suggested the existence of
a common pathogenic mechanism.3 Mutations
in LMNA cause several tissue-specific dis-
eases: the autosomal dominant form of
EDMD,2 the autosomal recessive form of
EDMD,4 the limb-girdle muscular dystrophy
type 1B (LGMD 1B),5 the dilated cardiomyopa-
thy and conduction-system disease (CMD-
CD),6 the Dunningan-type familial partial
lipodystrophy (FPLD2),7 and the Charcot-Marie
Tooth disorder type 2 (CMT 2B1).8 Each dis-
ease selectively strikes one or more specific
tissues, including skeletal and cardiac muscle,
tendons, adipose tissue, and peripheral neu-
rons. 
A further group of laminopathies has been
then identified, characterized by a systemic
involvement of almost all the tissues, which
undergo premature senescence. The progeric
laminopathies include the Hutchinson-Gilford
progeria, syndrome (HGPS)9,10 atypical
progeroid syndrome,11 mandibuloacral dyspla-
sia (MADA),12 and restrictive dermopathy
(RD).13
Typical nuclear abnormalities consisting of
altered nuclear envelope/lamina structure and
focal loss of heterochromatin are observed in
fibroblasts, myoblasts and muscle tissue from
EDMD1 patients.14,15 Characteristic non-uni-
form distribution of both lamin A/C and emerin
have been reported in skin fibroblasts from
EDMD2 patients.16,17 Ultrastructural alterations
include  nuclear lamina thickening, nuclear
pore clustering,16 as well as focal absence of
heterochromatin and loss of contact between
heterochromatin and the nuclear lamina.16,18
No accumulation of abnormal prelamin A has
been found in either biopsies or cultured cells
from EDMD2 patients.19 Fibroblasts from
FPLD2 patients present characteristic nuclear
alterations, due to the accumulation of abnor-
mal amounts of prelamin A.20,21 The dysmor-
phic FPLD2 nuclei present intranuclear
prelamin A aggregates, an enlarged and irreg-
ular nuclear profile, and a reduced amount of
peripheral heterochromatin.22
In dermal fibroblasts from HGPS, a-WS and
MADA patients, typical nuclear alterations
have been observed, mainly consisting in local
or total loss of peripheral heterochromatin,
associated with blebs and invaginations of the
nuclear lamina.22-24 In HGPS cells, the worsen-
ing of chromatin alterations have been report-
ed to increase with the age of the patient, as
well as with the increasing amount of prog-
erin.23,25,26 The cellular phenotype of RD, deter-
mined by accumulation of farnesylated
prelamin A, causes severe nuclear envelope
and chromatin abnormalities.27
Pathogenic mechanisms
The impressive variety of disease pheno-
types of laminopathies rises the question of
how mutation of a gene expressed in nearly
every differentiated cell could give rise to many
tissue-restricted pathologies. Besides their
role in maintaining, in association with B-type
lamins, the mechanical stability of the nuclear
envelope (NE) throughout the phases of the
cell cycle, A-type lamins and associated NE pro-
teins represent scaffolds for molecular interac-
tion with elements that regulate DNA synthe-
sis and repair, higher-order chromatin organi-
zation, nuclear positioning, gene transcrip-
tion, and cell differentiation.28,29 Many of these
functions involve lamin A interplay with signal
transduction pathways, transcription factors
and chromatin-associated proteins. On this
basis, different pathogenic mechanisms of
laminopathies have been proposed which
include: nuclear envelope defects affecting
nuclear stiffness,29,30 nuclear envelope defects
as determinants of altered nucleo-cytoplasmic
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interplay,31,32 altered cell cycle control,33 telom-
ere dysfunction,34 altered cellular sig-
nalling,35,36 altered stem cell functioning.37,38
In the present review we will focus mainly
on two further pathogenic mechanisms: i)
alterations of the nuclear morphology affecting
chromatin rearrangement; ii) altered DNA
repair due to oxidative stress.
Alterations of nuclear morphology affecting the chromatin arrangement
Alterations of nuclear morphology are pres-
ent in many types of laminopathies, frequently
associated with alterations of the chromatin
arrangement. Interestingly, distinct altered
patterns of chromatin distribution character-
ize different classes of laminopathies. Severe
nuclear abnormalities have been reported in
HGPS, a-WS, RD and MADA cells, including
lobulation, blebbing, and loss of heterochro-
matin.22,24-27,39 Aberrant nuclear morphology
results in cellular senescence, down-regula-
tion of transcription, and apoptosis.20,40
Furthermore, there is increasing evidence of a
role for lamins in the regulation of epigenetic
marks in chromatin. Loss of heterochromatin
in HGPS and RD cells is associated with down-
regulation of trimethylation at Lys-9 of histone
H3 (H3K9), and reduced association with het-
erochromatin protein 1a (HP1a).23,27 Cells
from older MADA patients also exhibit loss of
peripheral heterochromatin, together with
mislocalization of HP1b, trimethylated H3K9,
and LBR.24 In all these cases, the nuclear
defects appear to be not related to a loss of
mature wild-type lamin A, but to a dominant-
negative effect of aberrant prelamin A accumu-
lation.41
In laminopathies affecting the muscle,
nuclear alterations, that include nuclear lami-
na thickening, nuclear pore clustering, and
focal detachment of peripheral heterochro-
matin, appear to be related to a loss of mature
wild-type lamin A and to defective lamin phos-
phorylation.42,43 Alterations of the nuclear mor-
phology occurring in muscular laminopathies
also characterize sarcopenia, the age-related
decline of muscle mass, strength and quality in
elderly. It has been recently reported, by means
of in situ immunocytochemistry, that the activ-
ity of pre-mRNA splicing and cleavage is
impaired in the myonuclei of old muscles44 and
that similar alterations are detectable in cul-
tured myoblasts from DM2 patients,45 suggest-
ing the possibility that these nuclear alter-
ations might represent the basis of common
pathogenic mechanisms in sarcopenia,
myotonic dystrophy and laminopathies.46
Alterations in the nuclear arrangement have
been reported in the tissues affected in differ-
ent laminopathies and in cells cultured in vitro
obtained from laminopathic patients or animal
models of laminopathies. On the other hand,
the specificity of nuclear alterations which
characterize systemic laminopathies causing
premature senescence with respect to those
detected in muscular laminopathies, suggests
that different mechanisms are involved in the
pathogenesis of the two classes of lamino -
pathies. In fact, the accumulation of farnesylat-
ed prelamin A occurring in systemic
laminopathies results in defective interactions
of the nuclear envelope with chromatin-associ-
ated proteins such as HP1, thus impairing the
correct localization of heterochromatin
domains at the nuclear periphery, and could
have a repressive effect on gene transcription
of chromosome domains or tissue-specific
gene loci.47,48 In muscular laminopathies,
nuclear alterations are less evident49 and main-
ly detectable with immunocytochemical meth-
ods, such as defects related to defective lamin A
phosphorylation,42 altered pRb-mediated activa-
tion of cellular differentiation,50 excess accu-
mulation of phosphorylated Smad2 and Smad3
in nuclei.51 It is also conceivable that, as it has
been reported in sarcopenia and myotonic dys-
trophy,46 pre-mRNA splicing and cleavage is
impaired in muscular laminopathies.  
Altered DNA repair due tooxidative stress
Oxidative stress refers to a cell state where
the production of reactive oxygen species
(ROS), mainly produced by mitochondria and
NADPH oxidases, is higher than its removal. In
response to oxidative stress, the gene expres-
sion is modulated in order to activate various
redox-transcription factors, such as Rb, p53,
NF-kB and FoxO;52 however, whilst oxidants in
the cytoplasm are able to activate this redox
signalling, oxidative stress in the nucleus
blocks this process.53
Recent evidence points to a relationship
between lamin mutation and altered ROS
metabolism.54 Accumulation of fanesylated
prelamin A in progeric laminopathies induces
excessive ROS and reduces the level of antiox-
idant enzymes.55-57 Apart from a direct damag-
ing effect to coding sequences, ROS can affect
the lamin structure, thus promoting cellular
senescence and susceptibility to ROS.55
Downstream effects of ROS include persistent
DNA damage,58 and telomere shortening,59
mechanisms that have been suggested to be
involved into the pathogenesis of
laminopathies. ROS accumulate at a higher
rate in HGPS fibroblasts, as well as in normal-
ly aged fibroblasts;56 this may contribute to
increased levels of DNA damage and may trig-
ger senescence in HGPS cells.60 Moreover,
oxidative stress appears involved in the patho-
genesis of FPLD, whose fibroblasts undergo
p16-dependent senescent arrest.21 Impaired
DNA repair, and genomic instability also char-
acterize MEFs of Zmpste24-null mice, as well
as bone marrow cells and HGPS or RD fibrob-
lasts undergoing premature senescence.61
Fibroblasts from HGPS and MADA patients
show increased amounts of basal phosphory-
lated histone variant H2AX (gH2AX), a marker
of DNA damage sites.62,63 Gamma-H2AX colo-
calizes with XPA foci, an essential factor of
nucleotide excision repair (NER) and not with
double-strand breaks (DBSs), suggesting that
the damage in HGPS cells may be different
from that accrued by other genotoxic agents.62
Furthermore, fibroblasts from HGPS patients
show a marked delay in the recruitment of p53
binding protein 1 (53BP1) to sites of DNA
repair.61
A dysfunctional lamina may influence ROS
in several ways, because the lamina serves a a
docking site for transcription factors and chro-
matin-associated proteins.35 In HGPS fibrob-
lasts and in ZMPSTE24-/- MEFs the recruitment
of the repair factor p53-binding protein
(53BP1) to sites of DNA damage is impaired,
as well as the presence of fragmented DNA
after irradiation.61 Expression of HGPS mutant
lamin A in HeLa cells increases the levels of
phosphorylated histone H2AX (g-H2AX), a hall-
mark of double strand breaks, and this is cor-
related with defects in DNA repair foci.64 Other
DNA damage signalling pathways, including
ATM and ATR kinases as well as Rad50 and
Rad51, are affected in HGPS and RD fibrob-
lasts.65 These findings suggest that defects in
the DNA repair machinery are due to expres-
sion of abnormal levels of farnesylated
prelamin A in progeric laminopathies. 
DNA damage-initiated genomic instability
as well as p53-mediated cell senescence and
apoptosis in response to DNA damage may
contribute to aging.66 In a recent study, it has
been demonstrated that whilst the DNA dam-
age induced by etoposide could be repaired in
progeroid fibroblasts, many of double strand
breaks (DSB) induced by ROS are unre-
pairable. Moreover, because the treatment
with a ROS scavenger can reduce the amount
of DSB, it has been suggested that the accu-
mulation of un-repairable DNA damages could
be mainly due to the ROS-generating environ-
ment present in progeroid fibroblasts.67
As far as the mechanism leading to DBS in
laminopathic cells is concerned, it has been
hypothesized that, in normal condition, the
nuclear lamina could represent a nuclear
shield against ROS, being a preferential dock-
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CAT, GPX and GST, whose concentration in the
nucleus are several fold higher than in the
cytosol.68 In the presence of mutant lamin A,
the formation of the nuclear shield could be
affected, resulting in a higher susceptibility to
oxidative stress.
A general relationship between ROS, mito-
chondrial dysfunction, and the pathophysiolo-
gy of muscular dystrophies (MDs) has been
widely reported.69,70 This relationship has been
further supported by genetic71 or pharmacolog-
ical reduction of the open probability of the
PTP which prevent myofiber injury in animal
models of MDs,72 as well as in patients with
collagen VI myopathies.73 In laminopathies,
accumulation of farnesylated prelamina A also
affects the expression of the mtDNA encoded
subunit II of the cytochrome oxidase comple IV
(COX 2), lowering the mitochondrial potential
and generating ROS;21 moreover, accumulation
of farnesylated prelamin A in Zmpste24-/- mice
also causes an increased mitochondrial
response to oxidative stress, further support-
ing a relationship between defective lamin A
processing and mitochondrial dysfunction.74
A relevant source of ROS in mitochondria is
represented by MAOs, located in the outer
mitochondrial membrane, that catalyze the
oxidative deamination of neurotransmitters
and dietary amines, generating hydrogen per-
oxide. MAO have been studied at the level of
nervous system,75 leukemic cells,76 and in car-
diac diseases.77 In skeletal muscle it has been
recently reported that ROS related to MAO
activity plays a pivotal role in loss of cell viabil-
ity and contractile derangements in different
animal models of MDs, causing oxidation of
myfibrillar proteins.78
Molecular targets for a pharmacological treatment of laminopathies
Farnesylated lamin A exerts a dominant
effect on the pathophysiology of HGPS25 and
MAD;24 farnesyl transferase inhibitors (FTIs)
can block prelamin A processing and reduce
the percentage of cells with misshapen
nuclei79 and recover nuclear transcription
activity.23,41
Signaling pathway required to maintain
normal stem cell function have been reported
to be perturbed in cells expressing high levels
of unprocessed prelamin A. In particular,
expression of progerin activates down-stream
effectors of the Notch signalling pathway and
alters the differentiation potential of stem
cells.80 Alterations of  signalling pathways
involved in regulation of stem cells, such as
Wnt, have been reported in Zmpste24 null
mice.81 FTI treatment of HGPS cells did not
result in a reduction in DNA double strand
breaks and damage checkpoint signalling, sug-
gesting that DNA damage accumulation and
aberrant nuclear morphology are independent
phenotypes due to accumulation of progerin.65
Ideally, the therapy of progeroid syndromes
needs to achieve both restoration of nuclear
morphology and transcriptional ability, as well
as improvement of DNA damage repair mecha-
nisms. Amino-bisphosphonates (N-BPs), that
are used to prevent osteoporosis and the risk
of pathological fractures in bone malignancies,
act as inhibitors of farnesyl-phyrophosphate
synthase, thus reducing the synthesis of both
geranyl-geranyl and farnesyl groups. Their
use, in combination with statins, reduces
nuclear defects and partly rescues the disease
phenotype in Zmpste24 null mice.82
Pharmacological inhibitors of ERK1/2, whose
hyperactivation has been related to the patho-
genesis of DCM in EDMD,83 have been found to
block the development of cardiomyopathy in
LmnaH222P/H222P mice, before the appearance of
clinical symptoms.84 We have recently reported
that activation of the m-TOR-dependent
autophagic pathway using rapamycin can
counteract progerin accumulation in HGPS
cells, leading to the rescue of the chromatin
phenotype of senescent cells.85 The availability
of a drug capable of triggering degradation of
farnesylated prelamin A paves the way to the
treatment of other laminopathies featuring
accumulation of farnesylated prelamin forms
different from progerin. The treatment of
progeroid fibroblasts with the ROS scavenger
N-acetyl cysteine (NAC) has been demonstrat-
ed to reduce the levels of un-repairable DSB
and to improve their growth rate in culture.
Because the ROS-generating environment is
the primary cause of the accumulation of un-
repairable DNA damage, the use of ROS scav-
engers in conjunction with FTIs might improve
quality of life for progeric laminopathic
patients.67
The recent demonstration that pargyline, an
MAO inhibitor, is able to reduce ROS accumu-
lation and exerts a beneficial effect on the dys-
trophic phenotype in mice models of collagen
VI and Duchenne myopathies, adds evidence of
the pivotal role of mitochondrial dysfunction in
different muscular dystrophies78 and suggest a
therapeutic potential for MAO inhibitors also
in laminopathies. Determining the molecular
mechanisms by which the loss of A-lamins
impacts on the different pathways regulating
chromatin rearrangements, and DNA repair in
the presence of increased ROS production, will
be fundamental not only for understanding the
pathogenic mechanisms but also for the devel-
opment of further therapeutic strategies to
treat these diseases. 
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